ストックスクリーナーアプリを入手
10.08
0.00%
0.00
前日終値:
$10.08
開ける：
$10.08
24時間の取引高:
7,178
Relative Volume:
0.12
時価総額：
$220.83M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-0.40%
1か月 パフォーマンス:
+0.50%
6か月 パフォーマンス:
+20.48%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$10.07
$10.09
1週間の範囲:
$10.06
$10.12
52週間の値動き範囲:
$10.00
$10.20
Translational Development Acquisition Corp Stock (TDAC) Company Profile
TDAC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TDAC
Translational Development Acquisition Corp
|
10.08 | 220.83M | 0 | 0 | 0 | 0.00 |
|
LION
Lionsgate Studios Corp
|
7.43 | 2.19B | 3.13B | 50.80M | 555.00M | 0.1772 |
|
AACT
Ares Acquisition Corporation Ii
|
11.17 | 698.13M | 0 | 16.92M | -1.35M | 0.29 |
|
GATE
Marblegate Acquisition Corp
|
40.00 | 533.61M | 0 | -3.58M | -1.81M | -0.30 |
|
ANSC
Agriculture Natural Solutions Acquisition Corp
|
10.64 | 458.85M | 0 | 1.30M | 0 | 0.0301 |
|
AAM
Aa Mission Acquisition Corp
|
10.28 | 452.05M | 0 | 0 | 0 | 0.00 |
Translational Development Acquisition Corp Stock (TDAC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-09-21 | 開始されました | Northland Capital | Outperform |
Translational Development Acquisition Corp (TDAC) 最新ニュース
Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development - Yahoo Finance
Translational Development Acquisition Corp. Announces that the Separate Trading of its Class A Ordinary Shares and Warrants has Commenced - Yahoo Finance
Major SPAC Update: TDACU Splits Units into Separate Shares & Warrants Trading - StockTitan
Trident Acquisitions stock hits 52-week high of $10.08 By Investing.com - Investing.com Australia
Trident Acquisitions stock hits 52-week high of $10.08 - Investing.com
Ocean Biomedical Announces Breakthrough Findings in - GlobeNewswire
ImmuPharma (LON:IMM) Stock Price Up 9.3% – Here’s Why - Defense World
TDACU stock touches 52-week low at $10 amid market challenges - Investing.com
TDACU stock touches 52-week low at $10.01 amid market shifts - Investing.com UK
ICR, the Leading SPAC Communications and Advisory Firm, Publishes its Yearend 2024 SPAC Market Update & Outlook - Business Wire
Translational Development (TDACU) Raises $172.5M in Successful Nasdaq IPO, Begins Trading - StockTitan
Translational Development Acquisition Corp. (TDACU) Prices $150M IPO - SPACInsider
Valink Therapeutics Appoints Biopharmaceutical Veteran Martin D. Williams as Chair of the Board of Directors and Names Scientific Advisory Board - Business Wire
Rapid effects of valproic acid on the fetal brain transcriptome: implications for brain development and autism - Nature.com
Mestag Therapeutics Expands Leadership Team and Appoints Head of Development and General Counsel - GlobeNewswire
IPO NewsUS IPO Weekly Recap: Sizable tech and biotech IPOs are joined by a flurry of small names - Renaissance Capital
(PDF) Measuring Translation Competence Acquisition - ResearchGate
NImmune Biopharma Announces R&D Collaboration with BioTherapeutics, Inc. to Advance the Next Wave of Inflammation and Immunology Precision Medicines - Business Wire
Research and development center Cambridge, Massachusetts - Bristol Myers Squibb
Congruence Therapeutics Appoints Experienced Drug Developer Michael D. Harvey, Ph.D. as Chief Development Officer - PR Newswire
Novo Nordisk Expands Boston Area Research and Early Development - Genetic Engineering & Biotechnology News
Merck to Acquire Caraway Therapeutics, Inc. - Business Wire
Locks on Translation Initiation May Restrain Cancer - Genetic Engineering & Biotechnology News
Pioneering Innovative Drug Development at Cambridge Crossing Facility - Bristol Myers Squibb
SSI Strategy and NDA Group Combine to Form Best-in-Class Global Life Sciences Consultancy - Business Wire
FirstEnergy issues earnings report - 69News WFMZ-TV
Launching Revvity: A Scientific Solutions Company Powering Innovation from Discovery to Cure - News-Medical.Net
NImmune Biopharma Announces Precision Medicine Research Collaboration with NIMML Institute to Advance the Clinical Development of its LANCL Immunoregulatory Therapeutic Pipeline - Business Wire
Zura Bio Announces Appointment of Chief Scientific Officer - Business Wire
Edgewise Therapeutics Appoints Marc Semigran, M.D., As Chief Development Officer - Business Wire
Special Purpose Acquisition Company (SPAC) News and Analysis - SPACInsider
IPO Pricings Archives - SPACInsider
Translation regulatory factor BZW1 regulates preimplantation embryo development and compaction by restricting global non-AUG Initiation - Nature.com
A Stone Capital-backed SPAC braves the blank check waters, looking to grab a $150M deal - Endpoints News
Gate Neurosciences Emerges from Stealth with a Portfolio of Next-Generation Therapies for Central Nervous System Diseases - Business Wire
Oak Hill Bio Appoints Tauhid Ali as First Chief Executive Officer - Business Wire
VeriSIM Life Announces Acquisition of Molomics Biotech - Business Wire
Quotient integrates drug substance into platform - Speciality Chemicals Magazine
BioSpace Movers & Shakers, Jan. 21 - BioSpace
Third Rock Ventures Promotes David Kaufman, M.D., Ph.D., to Partner - citybiz
Amador Bioscience Announces the Completion of $60 Million Series B+ Round Financing - BioSpace
Research and Development grant cheat sheet - University of Sydney
Crown Bioscience Unveils New Identity - Business Wire
A red blood cell disease meets a company with a plasma protein heritage - Nature.com
CrownBio Acquires OcellO B.V. to Expand Its Preclinical In Vitro Drug Development Service Offerings - Business Wire
BioSpace Movers & Shakers, March 19 - BioSpace
Horizon Therapeutics plc Completes Acquisition of Viela Bio, Inc. - Business Wire
BioSpace Movers & Shakers: MoMa Therapeutics, Cerevance, Glympse Bio and More - BioSpace
Horizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio - Business Wire
(PDF) Cultural, textual and linguistic aspects of legal translation: A model of text analysis for training legal translators - ResearchGate
Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development - The Lancet
Translational Development Acquisition Corp (TDAC) 財務データ
Translational Development Acquisition Corp (TDAC) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
5.30%
0.00%
大文字化:
|
ボリューム (24 時間):